Cargando…
Effectiveness of Recombinant Human Growth Hormone Therapy for Children With Phelan-McDermid Syndrome: An Open-Label, Cross-Over, Preliminary Study
BACKGROUND: Phelan-McDermid syndrome (PMS), also known as the 22q13. 3 deletion syndrome, is a rare neurodevelopmental syndrome with approximately 2,800 patients reported worldwide. Previous pilot study demonstrated that IGF-1 could significantly improve in both social impairment and restrictive beh...
Autores principales: | Li, TianXiao, Xie, Ruijin, Zhao, Jinling, Xu, Hua, Cui, Ying, Sun, Chenyu, Wang, Chunhong, Liu, Yueying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888442/ https://www.ncbi.nlm.nih.gov/pubmed/35250656 http://dx.doi.org/10.3389/fpsyt.2022.763565 |
Ejemplares similares
-
Understanding Behavior in Phelan-McDermid Syndrome
por: Landlust, Annemiek M., et al.
Publicado: (2022) -
A case report of Phelan-McDermid syndrome: preliminary results of the treatment with growth hormone therapy
por: Xie, Rui Jin, et al.
Publicado: (2021) -
Correction to: A case report of Phelan-McDermid syndrome: preliminary results of the treatment with growth hormone therapy
por: Xie, Rui Jin, et al.
Publicado: (2021) -
Characterisation of the clinical phenotype in Phelan-McDermid syndrome
por: Burdeus-Olavarrieta, Mónica, et al.
Publicado: (2021) -
Psychiatric illness and regression in individuals with Phelan-McDermid syndrome
por: Kohlenberg, Teresa M., et al.
Publicado: (2020)